The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients

Hirasawa, Kazuhiro; Okamoto, Isaku; Motohashi, Ray; Sato, Hiroki; Takase, Soichiro; Agata, Ayumi; Takeda, Atsuo; Tsukahara, Kiyoaki

doi:10.1016/j.anl.2017.01.005

Cited by 11 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, comparative studies of the direct cytotoxicity of both classical and molecular-targeted drugs against human malignant as well as non-malignant cells has been limited. In contrast to our expectation, several molecular-targeted drugs showed side effects, such as interstitial pneumonia, dermatitis and mucositis/stomatitis (4) and aggravation of cardiotoxicity (5).…”

contrasting

confidence: 99%

In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs

et al. 2019

View full text Add to dashboard Cite

Background/Aim: The aim of the study was to evaluate the antitumor potential and combination effects of chemotherapeutic drugs. Materials and Methods: The cytotoxicity of 20 drip-type classical and molecular-targeted anticancer drugs was examined against 4 human oral squamous cell carcinoma cell lines and 5 human oral normal mesenchymal and epithelial cells. Cell cycle progression was monitored by a cell sorter. Combination effect was evaluated by combination index. Results: Most of the classical anticancer drugs showed much higher antitumor activity than moleculartargeted drugs, except bortezomib. Among 12 classical anticancer drugs, taxanes and gemsitabine showed the highest tumor-specificity (TS) and potency-selectivity expression (PSE) values, whereas platinum analogs showed the least TS value. Combination of two classical or a classical and a moleculartargeted drug showed mostly additive or antagonistic effect. 5-FU and cisplatin did not produce a subG 1 population, but induced G 2 /M or G 1 /S arrest, regardless of the addition of cetuximab. Cetuximab, nibolumab and bortezomib showed potent keratinocyte toxicity. Conclusion: The present TS monitoring system may provide useful information for building up the treatment regimens of anticancer drugs.

show abstract

contrasting

confidence: 99%

In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs

et al. 2019

View full text Add to dashboard Cite

show abstract

“…On the other hand, DI-IP is one of the most serious adverse events associated with the use of anticancer drugs, and the onset of DI-IP differs between races. The IP prevalence among Japanese populations is has been reported as particularly high compared with the populations of Western countries [ 9 , 10 ]. Despite the excellent therapeutic effect, we also reported drug-induced interstitial pneumonia (DI-IP) during SCT in 138 patients with R/M HNSCC (incidence rate, 7.2%) [ 8 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

et al. 2022

View full text Add to dashboard Cite

Objectives The benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration. Materials and methods We retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45). Results The objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B. Conclusion Although PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended.

show abstract

“…This takes into consideration age, comorbidities, and the presence of contraindications for cisplatin, such as impaired renal function, poor general health, bone marrow suppression, and impaired hearing. If patients are considered unfit for cisplatin alternative options to increase the anti-tumor effect of radiotherapy include the addition of cetuximab [ 4 ]. However, patients treated with cetuximab in combination with radiotherapy may also experience considerable amounts of toxicity, specifically leucopenia, neutropenia, and mucositis [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy

Huiskamp

Chargi

Devriese

et al. 2020

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Purpose This study aims to investigate the predictive value of low skeletal muscle mass (SMM) for cetuximab dose-limiting toxicity (DLT) and its prognostic value in head and neck squamous cell carcinoma (HNSCC) patients treated with concomitant cetuximab and radiotherapy. Methods Patients diagnosed with HNSCC and treated with primary or adjuvant concomitant cetuximab and radiotherapy were included. Clinical and demographic variables were retrospectively retrieved and SMM was measured at the level of the third cervical vertebra using pre-treatment diagnostic computed tomography or magnetic resonance imaging. An optimal cutoff value for low SMM was determined based on the lowest log-likelihood associated with cetuximab DLT. A multivariate linear regression model was used to determine predictive factors for cetuximab DLT. The prognostic value of low SMM for disease-free and overall survival was analyzed using Kaplan-Meier curves. Results The optimal cutoff value for low SMM as a predictor of cetuximab DLT was an LSMI ≤ 45.2 cm 2 /m 2. Of the 91 included patients, 74.7% had low SMM and 30.8% experienced cetuximab DLT. At multivariate analysis, low SMM had no predictive value for DLT (OR 0.83; 95% CI 0.27-2.56; p = 0.74). The Kaplan-Meier curve demonstrated that patients with low SMM had significantly lower overall survival (Log Rank χ 2 = 5.87; p = 0.02). Conclusion Low SMM is highly prevalent in HNSCC patients treated with concomitant cetuximab and radiotherapy. Low SMM has no predictive value for cetuximab DLT in HNSCC patients. Low SMM is probably not a prognostic factor for overall survival in highly selected HNSCC patients treated with concomitant cetuximab and radiotherapy and unfit for platin-based chemotherapy.

show abstract

The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients

Cited by 11 publications

References 23 publications

In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs

In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy

Contact Info

Product

Resources

About